Cargando…

Integrated in silico – in vitro strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic effect with allopurinol and febuxostat

Xanthine oxidase (XO) has been well-recognized as a validated target for the treatment of hyperuricemia and gout. Currently, there are two drugs in clinical use that shut down XO overactivity, allopurinol and febuxostat; however, detrimental side effects restrict their applications. Propolis is a un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghallab, Dina S., Shawky, Eman, Metwally, Ali M., Celik, Ismail, Ibrahim, Reham S., Mohyeldin, Mohamed M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2022
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979054/ https://www.ncbi.nlm.nih.gov/pubmed/35425287 http://dx.doi.org/10.1039/d1ra08011c

Ejemplares similares

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
por: Jordan, Andreas, et al.
Publicado: (2018)

Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats
por: Tayama, Yoshitaka, et al.
Publicado: (2022)

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
por: Nomura, Johji, et al.
Publicado: (2014)

Comprehensive metabolomics unveil the discriminatory metabolites of some Mediterranean Sea marine algae in relation to their cytotoxic activities
por: Ghallab, Dina S., et al.
Publicado: (2022)

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
por: Higa, Yoshiki, et al.
Publicado: (2023)

Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress
por: George, Jacob, et al.
Publicado: (2009)

Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia
por: Wei, Shuoyu, et al.
Publicado: (2020)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition
por: Li, Yong, et al.
Publicado: (2016)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Maternal-to-fetal allopurinol transfer and xanthine oxidase suppression in the late gestation pregnant rat
por: Kane, Andrew D, et al.
Publicado: (2013)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice
por: Karve, Ashwini V., et al.
Publicado: (2013)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Xanthine Oxidase Inhibitor, Allopurinol, Prevented Oxidative Stress, Fibrosis, and Myocardial Damage in Isoproterenol Induced Aged Rats
por: Sagor, Md. Abu Taher, et al.
Publicado: (2015)

Effects of Allopurinol as a xanthine oxidase inhibitor on depressive-like behavior of rats and changes in serum BDNF level
por: Jahromy, Mahsa Hadipour, et al.
Publicado: (2022)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

Long-Term Inhibition of Xanthine Oxidase by Febuxostat Does Not Decrease Blood Pressure in Deoxycorticosterone Acetate (DOCA)-Salt Hypertensive Rats
por: Szasz, Theodora, et al.
Publicado: (2013)

Xanthine Oxidase Inhibitor Allopurinol Prevents Oxidative Stress‐Mediated Atrial Remodeling in Alloxan‐Induced Diabetes Mellitus Rabbits
por: Yang, Yajuan, et al.
Publicado: (2018)

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
por: Rey, Amayelle, et al.
Publicado: (2019)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
por: Park, Seokwoo, et al.
Publicado: (2022)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase
por: Sekine, Mai, et al.
Publicado: (2023)

Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK
por: Nomura, Johji, et al.
Publicado: (2013)

In silico design and synthesis of hesperitin derivatives as new xanthine oxidase inhibitors
por: Malik, Neelam, et al.
Publicado: (2019)

In silico design and synthesis of targeted rutin derivatives as xanthine oxidase inhibitors
por: Malik, Neelam, et al.
Publicado: (2019)

Inhibition of Xanthine Oxidase by Allopurinol Prevents Skeletal Muscle Atrophy: Role of p38 MAPKinase and E3 Ubiquitin Ligases
por: Derbre, Frederic, et al.
Publicado: (2012)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice
por: Mizuno, Yu, et al.
Publicado: (2019)

Xanthine oxidase inhibitors and sepsis
por: Ramos, Maria Fátima de Paula, et al.
Publicado: (2018)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8infckss4v5qt8g1rncgunejcc